Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

83.30CHF
16 Aug 2019
Change (% chg)

CHF1.50 (+1.83%)
Prev Close
CHF81.80
Open
CHF81.50
Day's High
CHF83.30
Day's Low
CHF80.30
Volume
8,490
Avg. Vol
9,850
52-wk High
CHF141.90
52-wk Low
CHF76.10

About

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): €1,965.91
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 29.89 32.67
EPS (TTM): 0.24 -- --
ROI: 5.61 14.89 14.48
ROE: 6.12 16.01 15.78

BRIEF-Cosmo Pharmaceuticals: Canadian Agency Approval Of Eleview

* ELEVIEW(R) WILL BE COMMERCIALIZED IN CANADA BY PENDOPHARM (DIVISION OF PHARMASCIENCE INC.) UNDER AN EXISTING LICENSE AND SUPPLY AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Jul 2019

BRIEF-Cosmo Pharmaceuticals Announces Publication Of Positive Review Of Aemcolo

* ANNOUNCED TODAY PUBLICATION OF A REVIEW OF AEMCOLO IN A CLINICAL INVESTIGATION THAT HIGHLIGHTS ITS SAFETY AND EFFECTIVENESS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

21 Jun 2019

BRIEF-FDA Accepts NDA Filing For Cosmo Pharmaceuticals' Remimazolam

* FDA ACCEPTS FILING OF NDA FOR REMIMAZOLAM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Jun 2019

BRIEF-Cosmo Pharmaceuticals Announces Distribution Agreement And Further Collaboration Agreement

* NEW EXCLUSIVE DISTRIBUTION AGREEMENT FOR ELEVIEW WITH MEDTRONIC IN THE US, CHINA AND SOUTH AMERICA

08 May 2019

BRIEF-Cosmo Pharmaceuticals: FDA Allowance Of IND Application For CB-03-10

* FDA Allowance Of IND Application For CB-03-10 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

07 May 2019

BRIEF-Cosmo Pharmaceuticals: Worldwide Distribution Agreement Of AI Device In Colonoscopy With Medtronic

* COSMO PHARMACEUTICALS ANNOUNCES REVOLUTIONARY ARTIFICIAL INTELLIGENCE DEVICE IN COLONOSCOPY TO DETECT LESIONS AND WORLDWIDE DISTRIBUTION AGREEMENT WITH MEDTRONIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Apr 2019

BRIEF-Cosmo Pharmaceuticals Announces Submission Of Remimazolam NDA To FDA

* ANNOUNCES SUBMISSION OF REMIMAZOLAM NDA TO FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Apr 2019

BRIEF-Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

* FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017

29 Mar 2019

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates

No consensus analysis data available.